Adimab has the ability to rapidly clone hundreds of fully-human or murine antibodies from single B cells into our yeast system.
Partners typically provide murine lymphoid tissues or human PBMCs. Within approximately 6 weeks, at least 200 ug of sequence-verified monoclonal IgGs are available for biological assessment.
Once antibodies are identified that have the desired biological activity, we can quickly improve the lead candidates using our various optimization techniques. Optimization may include engineering in higher affinity, developability, and species cross-reactivity.
Our key advantages are:
- Ability to clone and produce hundreds of IgGs with native H-L pairing from human or murine sources in six weeks.
- Rapid improvement of lead candidates using a variety of optimization techniques.